For years, artificial intelligence (AI) has been closely associated with the big tech companies. But it is becoming a core competitive advantage across industries. The healthcare and biotech sector, in particular, is using AI to fundamentally transform how products are discovered, developed, and delivered. One classic example of that is Eli Lilly (LLY), a global pharmaceutical company that develops, manufactures, and sells medicines in diabetes & obesity, oncology, immunology, and neuroscience.
Valued at $901.8 billion, LLY stock has fallen 12% year-to-date (YTD), compared to the S&P 500 Index’s ($SPX) dip of 4%.
